A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder

Journal of Clinical Psychiatry

Volumn 75, Issue 9, 2014, Pages 1010-1018

  Corp, Stephanie A ^a   Gitlin, Michael J ^a   Altshuler, Lori L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ARMODAFINIL; ATOMOXETINE; DEXAMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESCITALOPRAM; FLUOXETINE; LISDEXAMFETAMINE; LITHIUM CARBONATE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; OLANZAPINE; PEMOLINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROATE SEMISODIUM; CENTRAL STIMULANT AGENT;

ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; BECK DEPRESSION INVENTORY; BIPOLAR DEPRESSION; BRIEF FATIGUE INVENTORY; CARDIOVASCULAR RISK; CATECHOLAMINE RELEASE; CEREBROVASCULAR ACCIDENT; CLINICAL GLOBAL IMPRESSION SCALE; COMBINATION CHEMOTHERAPY; CONSTIPATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SEEKING BEHAVIOR; DSM-IV; ELECTROCONVULSIVE THERAPY; EPWORTH SLEEPINESS SCALE; FATIGUE SEVERITY SCALE; GLOBAL ASSESSMENT OF FUNCTIONING; HAMILTON DEPRESSION RATING SCALE; HEART DEATH; HEART FUNCTION; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INSOMNIA; INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY; LONG TERM CARE; MAJOR DEPRESSION; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NUCLEUS ACCUMBENS; POSTSYNAPTIC POTENTIAL; PREFRONTAL CORTEX; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC SYMPTOM ASSESSMENT SCALE; PSYCHOMETRY; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SELF REPORT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SUICIDAL IDEATION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATION; DRUG POTENTIATION; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSIVE DISORDER, MAJOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME;

EID: 84922012669     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13r08851     Document Type: Review

References (28)

1. Rasmussen N. America's first amphetamine epidemic 1929-1971: a quantitative and qualitative retrospective with implications for the present. Am J Public Health. 2008;98(6):974-985. doi:10.2105/AJPH.207.10593 PubMed
2. Provigil (modafinil) [package insert]. Frazer, PA: Cephalon, Inc; 2010.
3. Strattera (atomoxetine hydrochloride) [package insert]. Indianapolis, IN: Lilly USA; 2012.
4. Korston TR. Drugs of abuse. In: Katzung BG, ed. Basic and Clinical Pharmacology. 9th ed. New York, NY: McGraw-Hill Medical Publications; 2004:521-523.
5. Michelson D, Adler LA, Amsterdam JD, et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(4):582-587. doi:10.408/JCP.v68n0414 PubMed
6. Fawcett J, Kravitz HM, Zajecka JM, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991;11(2):127-132. PubMed
7. El-Mallakh RS. An open study of methylphenidate in bipolar depression. Bipolar Disord. 2000;2(1):56-59. doi:10.1034/j.139-5618.20.020108.x PubMed
8. Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord. 2004;6(5):416-420. doi:10.1/j.139-5618.204.0132.x PubMed
9. Parker G, Brotchie H. Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatr Scand. 2010;121(4):308-314. doi:10.1/j.160-047.209.01434.x PubMed
10. Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety. 1998;7(2):89-91. doi:10.102/(SICI)1520-6394(198)7:2<89:AID-DA8>3.0.CO;2-0 PubMed
11. Markovitz PJ, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol. 2003;23(2):207-209. doi:10.1097/04714-203040-017 PubMed
12. DeBattista C, Lembke A, Solvason HB, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. 2004;24(1):87-90. doi:10.1097/01.jcp.0104910.75206.b9 PubMed
13. Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007;19(3):153-159. doi:10.1080/10401230701464858 PubMed
14. Carpenter LL, Milosavljevic N, Schecter JM, et al. Augmentation with openlabel atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005;66(10):1234-1238. doi:10.408/JCP.v6n105 PubMed
15. Papakostas GI, Petersen TJ, Burns AM, et al. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatr Res. 2006;40(4):370-373. doi:10.1016/j.jpsychires.205.04.013 PubMed
16. Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebocontrolled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653-656. doi:10.1097/01.jcp.0246212.03530.fd PubMed
17. Ravindran AV, Kennedy SH, O'Donovan MC, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebocontrolled trial. J Clin Psychiatry. 2008;69(1):87-94. doi:10.408/JCP.v69n012 PubMed
18. Trivedi MH, Cutler AJ, Richards C, et al. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry. 2013;74(8):802-809. doi:10.408/JCP.13m08360 PubMed
19. DeBattista C, Doghramji K, Menza MA, et al; Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary doubleblind, placebo-controlled study. J Clin Psychiatry. 2003;64(9):1057-1064. doi:10.408/JCP.v64n091 PubMed
20. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66(1):85-93. doi:10.408/JCP.v6n012 PubMed
21. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164(8):1242-1249. doi:10.176/api.ajp.207.06060981 PubMed
22. Dunlop BW, Crits-Christoph P, Evans DL, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebocontrolled study. J Clin Psychopharmacol. 2007;27(6):614-619. doi:10.1097/jcp.0b013e31815abefb PubMed
23. Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71(10):1363-1370. doi:10.408/JCP.09m0590gry PubMed
24. Abolfazli R, Hosseini M, Ghanizadeh A, et al. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depress Anxiety. 2011;28(4):297-302. doi:10.102/da.20801 PubMed
25. Altshuler LL, Gitlin MJ, Mintz J, et al. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry. 2002;63(9):807-811. doi:10.408/JCP.v63n0910 PubMed
26. Gitlin MJ, Mintz J, Sokolski K, et al. Subsyndromal depressive symptoms after symptomatic recovery from mania are associated with delayed functional recovery. J Clin Psychiatry. 2011;72(5):692-697. doi:10.408/JCP.09m05291gre PubMed
27. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673-2683. doi:10.101/jama.201.1830 PubMed
28. Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry. 2012;169(2):178-185. doi:10.176/api.ajp.201.1010125 PubMed